International Journal of Obstetric Anesthesia
Volume 16, Issue 1 , Pages 29-34 , January 2007

Recombinant factor VIIa in massive postpartum haemorrhage

  • D. Karalapillai
    • ,
  • P. Popham

      Affiliations

    • Corresponding Author InformationCorrespondence to: Dr. Philip Popham, BSc, MBBS, FRCA, MD, Senior Principal Anaesthetist, affiliated to the Department of Obstetrics and Gynaecology, University of Melbourne, Australia.

,Accepted 1 September 2006.

References 

  1. Hedner U, Erhardsten E. Potential role of rFVIIa in transfusion medicine. Transfusion. 2002;42:114–124
  2. Kenet G, Walden R, Eldad A, Martinowitz U. Treatment of traumatic bleeding with recombinant factor VIIa. Lancet. 1999;354:1879
  3. Martinowitz U, Kenet G, Segal E, et al. Recombinant activated factor VII for adjunctive hemorrhage control in trauma. J Trauma. 2001;51:431–438
  4. Moscardo F, Perez F, de La Rubia J, et al. Successful treatment of severe intra-abdominal bleeding associated with disseminated intravascular coagulation using recombinant activated factor VII. Br J Haematol. 2001;114:174–176
  5. Hendriks H, van der Maaten D, de Wolf J, et al. An effective treatment of severe intractable bleeding after valve repair by one single dose of activated recombinant factor VII. Anesth Analg. 2001;93:287–289
  6. Friedrich PW, Geerdink MG, Spatoro M, et al. The effect of administration of recombinant factor VIIa on perioperative blood loss in patients undergoing transabdominal retropubic prostatectomy: The PROSE study. Blood Coagul Fibrinolysis. 2000;11:S129–S132
  7. Kalicinski P, Kaminski A, Drewniak H, et al. Quick correction of hemostasis in two patients with fulminant liver failure undergoing liver transplantation by recombinant activated factor VII. Transf Proc. 1999;31:375–379
  8. Shami VM, Caldwell SS, Hespenheide EE, et al. Recombinant activated factor VII for coagulopathy in fulminant hepatic failure compared with conventional therapy. Liver Transpl. 2003;9:138–143
  9. Why mothers die. A Report on the Confidential Enquiries into Maternal Deaths in the United Kingdom, 1994-1996. London: Department of Health, HMSO; 1998;
  10. Why mothers die. Report on Confidential Enquiries into Maternal Deaths in the United Kingdom, 2000-2002. London: RCOG Press; 2004;
  11. Drife J. Management of primary post partum haemorrhage. Br J Obstet Gynaecol. 1997;104:275–277
  12. Macphail S, Talks K. Massive post partum haemorrhage and management of disseminated intravascular coagulation. Curr Obstet Gynecol. 2004;14:123–131
  13. Mousa H, Walkinshaw S. Major post partum haemorrhage. Curr Opin Obstet Gynecol. 2001;13:595–603
  14. Ahonen J, Jokela R. Recombinant factor VIIa for life-threatening post-partum haemorrhage. Br J Anaesth. 2005;94:592–595
  15. Boehlen F, Morales MA, Fontana P, Ricou B, Irion O, Moerloose P. Prolonged treatment of massive postpartum haemorrhage with recombinant factor VIIa: case report and review of the literature. Br J Obstet Gynaecol. 2004;111:284–287
  16. Bouwmeester FW, Jonkhoff AR, Verheijen R, van Geijn H. Successful treatment of life threatening postpartum hemorrhage with recombinant activated factor VII. Obstet Gynecol. 2003;101:1174–1176
  17. Gidiri M, Noble W, Rafique Z, Patil K, Lindow S. Caeserean section for placenta praevia complicated by postpartum haemorrhage managed successfully with recombinant activated human coagulation factor VIIa. J Obstet Gynecol. 2004;24:925–926
  18. Haynes J, Laffan M, Plaat F. Use of recombinant activated factor VII in massive obstetric haemorrhage. Int J Obstet Anesth (in press).
  19. Price G, Kaplan J, Skowronski G. Use of recombinant factor VIIa to treat life-threatening non-surgical bleeding in a post partum patient. Br J Anaesth. 2004;93:298–300
  20. Segal S, Shemesh IY, Blumenthal R, et al. Treatment of obstetric hemorrhage with recombinant activated factor VII (rFVIIa). Arch Gynecol Obstet. 2003;268:266–267
  21. Zupancic Salek S, Sokolic V, Viskovic T, Sanjug J, Simic M, Kastelan M. Successful use of recombinant factor VIIa for massive bleeding after caesarean section due to HELLP syndrome. Acta Haematol. 2002;108:162–163
  22. Erber W, Perry D. Plasma and plasma products in the treatment of massive haemorrhage. Best Pract Clin Haematol. 2006;19:97–112
  23. Banninger H, Lammle B, Furlan M. Binding of alpha-thrombin to fibrin depends on the quality of the fibrin network. Biochem J. 1994;298:157–163
  24. Blomback B, Carlsson K, Fatah K, Hessel B, Procyk R. Fibrin in the human plasma gel architectures governed by rate and nature of fibrinogen activation. Thromb Res. 1994;75:521–538
  25. Gabriel D, Muga K, Boothroyd E. The effect of fibrin structure on fibrinolysis. J Biol Chem. 1992;267:259–263
  26. Mittal S, Watson H. A critical appraisal of the use of recombinant factor VIIa in acquired bleeding conditions. Br J Haematol. 2006;133:355–363
  27. McCall P, Story D, Karalapillai D. Audit of factor VIIa for bleeding resistant to conventional therapy following complex cardiac surgery. Can J Anaesth. 2006;53:926–933
  28. Boffard K, Riou B, Warren B, et al. Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials. J Trauma. 2005;59:8–15
  29. Clark AD, Gordon WC, Walker ID, Tait RC. ‘Last-ditch’ use of recombinant factor VIIa in patients with massive haemorrhage is ineffective. Vox Sang. 2004;86:120–124
  30. NovoSeven™ product information, Novo Nordisk Pharmaceuticals: Copenhagen, Denmark.
  31. Stainsby D, MacLennan S, Hamilton P. Management of massive blood loss: a template guideline. Br J Anaesth. 2000;85:487–491
  32. Martinowitz U, Michaelson M. Guidelines for the use of transfusion factor VII in uncontrolled bleeding: a report by the Israeli Multidisciplinary taskforce. J Thromb Haemost. 2005;3:640–648
  33. Levi M, Peters M, Buller H. Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: a systematic review. Crit Care Med. 2005;33:883–890
  34. Thompson A. When all else fails to stop massive bleeding from trauma. J Thromb Haemost. 2005;3:638–639
  35. Meng Z, Wolberg A, Monroe D, Hoffman M. The effect of temperature and pH on the activity of factor VIIa: implications for the efficacy of high dose factor VIIa in hypothermic acidotic patients. J Trauma. 2003;55:886–891
  36. Franchini M, Zaffanello M, Vaneri D. Recombinant factor VIIa. An update on its clinical use. Thromb Haemost. 2005;93:1027–1035
  37. Mitty HA, Sterling KM, Alvarez M, Gendler R. Obstetric hemorrhage: prophylactic and emergency arterial catheterization and embolotherapy. Radiology. 1993;188:183–187
  38. Tamizian O, Arulkumaran S. The surgical management of post-partum haemorrhage. Best Pract Res Clin Obstet Gynaecol. 2002;16:81–98
  39. Shamsi TS, Hossain N, Soomro N, et al. Use of recombinant factor VIIa for massive postpartum haemorrhage: case series and review of the literature. J Pak Med Assoc. 2005;55:512–515
  40. Spahn D, Tucci M, Makris M. Is recombinant factor VIIa the magic bullet in the treatment of major bleeding?. Br J Anaesth. 2005;94:553–555
  41. Milligan L, Bellamy M. Anaesthesia and critical care of Jehovah’s witnesses. Br J Anaesth (CEACCP). 2004;4:33–35
  42. Aledort L. rFVIIa: Its thrombogenicity. Thromb Haemost. 2000;84:522–523
  43. Peerlinck K, Vermylen J. Acute myocardial infarction following administration of recombinant activated factor VII (Novo Seven) in a patient with haemophilia A and inhibitor. Thromb Haemost. 1999;82:1775–1776
  44. Roberts H. Clinical experience with activated factor VII: focus on safety aspects. Blood Coagul Fibrinolysis. 1998;9:S115–S118
  45. Siegel L, Gerig L, Tuttenberg J, Demple C, Scharf J, Fiedler F. Cerebral sinus thrombosis in a trauma patient after recombinant activated factor VII infusion. Anesthesiology. 2004;100:441–443
  46. Biss TT, Hanley JP. Recombinant activated factor VII (rFVIIa/NovoSeven®) in intractable haemorrhage: use of a clinical scoring system to predict outcome. Vox Sang. 2006;90:45–52
  47. Aledort LM. Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity. J Thromb Haemost. 2004;2:1700–1708

PII: S0959-289X(06)00159-2

doi: 10.1016/j.ijoa.2006.09.001

International Journal of Obstetric Anesthesia
Volume 16, Issue 1 , Pages 29-34 , January 2007

Article Tools

* Image Usage & Resolution